Search for Cases

Case Details

Case Code: FINC137
Case Length: 7 Pages 
Period: 2008 - 2017   
Pub Date: 2018
Teaching Note: Available
Price:Rs.200
Organization : Lupin Limited
Industry : Pharmaceuticals
Countries : India
Themes: Risk Return Analysis in Corporate Finance
Case Studies  
Business Strategy
Marketing
Finance
Human Resource Management
IT and Systems
Operations
Economics
Leadership & Entrepreneurship

Lupin Stock: Risk and Return

 

ABSTRACT

 
On November 7, 2017, the Lupin stock hit a 52-week low of Rs.846.20 when the pharma major informed the NSE and the BSE about the warning letter it had received from the USFDA.Following the steep decline in the stock price, company's market valuation eroded by Rs 78.66 billion. Concerned over Lupin Ltd.’s margins, most of the brokerage houses cut their target price on the stock. Investors were left wondering whether they should sell the stock, hold it, or buy more. The present case uses the backdrop of Lupin stock price fluctuations to teach the concept of risk and return analysis.
 
Finance Case Studies | Case Study in Management, Operations, Strategies, Business Environment, Case Studies
or
Finance Case Studies | Case Study in Management, Operations, Strategies, Business Environment, Case Studies
or
PayPal (5 USD)

 

Issues

The case is structured to achieve the following teaching objectives:
  • Learn the significance of risk and return analysis
  • Learn how to calculate historical and expected returns on a particular stock and the market.
  • Learn how to calculate historical and expected risk of a particular stock and the market.
  • Learn how to measure the systematic risk (β) of a particular stock.
  • Check whether the stock is underpriced or overpriced using the CAPM model.
Contents
INTRODUCTION
ABOUT LUPIN
PHARMACEUTICAL INDUSTRY IN INDIA
USFDA WARNING LETTER
EXHIBITS

Keywords

Risk and return of stock; Market return and risk; Historical return and risk; Expected return and risk; Beta ;CAPM;Overpriced; Under priced

INTRODUCTION - Next Page>>